David Dicesar, MD
Endocrinology, Diabetes & Metabolism · East Syracuse, NYNPI 1689837734
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $214,265 of the $255,169 with a category attached, or 84.0%. Novo Nordisk accounts for 62.8% of it on its own, with 41 other manufacturers making up the rest. 2025 is the largest year on record at $52,059, 2.2 times the $23,523 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 592 payments — averaging $431.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$160K
- Dexcom, Inc.$51K
- Sanofi-aventis U.S. LLC$27K
- Johnson & Johnson$10K
- IBSA Pharma Inc.$2K
- Lilly USA, LLC$824
- plus $5K from 36 others
What the payments were for
- Consulting fees$1,1750%
- Speaking & faculty fees$214,26584%
- Travel & lodging$28,00411%
- Food & beverage$11,6955%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 206 | $160,134 |
| Dexcom, Inc. | 47 | $50,562 |
| Sanofi-aventis U.S. LLC | 38 | $27,433 |
| Johnson & Johnson | 19 | $9,632 |
| IBSA Pharma Inc. | 12 | $1,653 |
| Lilly USA, LLC | 59 | $824 |
| Amgen | 26 | $627 |
| Medtronic(2 entities) | 9 | $552 |
| AstraZeneca(2 entities) | 18 | $528 |
| Boehringer Ingelheim | 22 | $359 |
| Abbott | 15 | $282 |
| Ascendis Pharma Endocrinology Inc | 6 | $252 |
| Novartis | 11 | $240 |
| Pfizer | 12 | $231 |
| Tandem Diabetes Care, Inc. | 7 | $170 |
| Bayer | 9 | $165 |
| Corcept Therapeutics | 8 | $161 |
| Mannkind Corporation | 8 | $153 |
| Xeris Pharmaceuticals, Inc. | 7 | $131 |
| Recordati_rare_diseases_inc. | 5 | $109 |
| BETA Bionics, Inc. | 5 | $108 |
| AbbVie | 7 | $108 |
| Radius Health, Inc. | 5 | $93 |
| Amphastar Pharmaceuticals, Inc. | 4 | $77 |
| Sanofi | 1 | $72 |
| Amneal Pharmaceuticals LLC | 3 | $64 |
| Sequel Med Tech, LLC | 3 | $60 |
| Insulet Corporation | 2 | $43 |
| Ultragenyx Pharmaceutical Inc. | 2 | $42 |
| Amarin Pharma, Inc. | 2 | $37 |
| Madrigal Pharmaceuticals | 1 | $32 |
| GSK | 2 | $30 |
| Kyowa Kirin, Inc. | 1 | $29 |
| Cequr Corporation | 2 | $26 |
| Almatica Pharma LLC | 1 | $25 |
| Currax Pharmaceuticals LLC | 1 | $25 |
| Chiesi USA, Inc. | 1 | $23 |
| Exact Sciences | 1 | $20 |
| Tolmar, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$80,307
- RYBELSUS$51,797
- DEXCOM G7 GSS (161)$49,769
- TZIELD$20,643
- INVOKANA$9,416
- DEXCOM STELO GLUCOSE BIOSENSOR$8,880
- Tresiba$7,771
- Tirosint$3,000
- MINIMED 780G$273
- FARXIGA$232
- Prolia$175
- TOUJEO$118
- Yorvipath$107
How this compares
$255,169 in reported general payments places this provider in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 343 | $622,625 |
| JardianceEmpagliflozin | 157 | $226,723 |
| MounjaroTirzepatide | 48 | $88,362 |
| FarxigaDapagliflozin Propanediol | 59 | $80,660 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $69,002 |
| ProliaDenosumab | 35 | $60,608 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $56,986 |
| RybelsusSemaglutide | 21 | $53,860 |
| InvokanaCanagliflozin | 36 | $36,934 |
| Repatha SureclickEvolocumab | 21 | $32,050 |
| VascepaIcosapent Ethyl | 24 | $23,903 |
| KerendiaFinerenone | 19 | $23,363 |
| NovologInsulin Aspart | 45 | $19,240 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 73 | $17,906 |
| Cinacalcet Hcl | 30 | $15,510 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $160,134 | $695,726409 claims |
| Boehringer IngelheimJardiance | $359 | $226,723157 claims |
| Lilly USA, LLCMounjaro, Humalog, Insulin Lispro | $824 | $98,073102 claims |
| AstraZenecaFarxiga | $528 | $80,66059 claims |
| AmgenProlia | $627 | $60,60835 claims |
| Johnson & JohnsonInvokana | $9,632 | $36,93436 claims |
| BayerKerendia | $165 | $23,36319 claims |
| AbbVieSynthroid | $108 | $13,923162 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $64 | $7,098517 claims |
| IBSA Pharma Inc.Tirosint | $1,653 | $5,56917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in East Syracuse
- Steven ZygmontEast Syracuse$167K
- Robert BuschAlbany$2.7M
- Michael ShanikSmithtown$1.2M
- Ajay ChaudhuriBuffalo$888K
- Vinay KapoorManhasset$820K
- John BilezikianNew York$809K
- Barbara HirschManhasset$746K
- Martin GrajowerBronx$713K
- Anastasios ManessisNew York$656K
- Jonas LeibowitzYonkers$613K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.